Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 315
Filtrar
1.
Br J Cancer ; 105(4): 513-22, 2011 Aug 09.
Artículo en Inglés | MEDLINE | ID: mdl-21829205

RESUMEN

BACKGROUND: Given that HIV-protease inhibitors (HIV-PIs) are substrates/inhibitors of the multidrug transporter ABCB1, can induce ABCB1 expression, and are used in combination with doxorubicin for AIDS-Kaposi's Sarcoma (KS) treatment, the role that ABCB1 plays in mediating multidrug resistance (MDR) in a fully transformed KS cell line (SLK) was explored. METHODS: The KS cells were exposed to both acute and chronic treatments of physiological concentrations of different HIV-PIs (indinavir, nelfinavir, atazanavir, ritonavir, or lopinavir), alone or together with doxorubicin. The ABCB1 mRNA and protein expression levels were then assessed by qRT-PCR and western blotting, flow cytometry, and immunofluorescence. RESULTS: Chronic treatment of SLK cells with one of the five HIV-PIs alone or together resulted in increased resistance to doxorubicin. Co-treatment with one of the HIV-PIs in combination with doxorubicin resulted in a synergistic increase in resistance to doxorubicin, and the degree of resistance was found to correlate with the expression of ABCB1. The SLK cells were also revealed to be cross-resistant to the structurally unrelated drug paclitaxel. CONCLUSION: These studies suggest that ABCB1 is primarily responsible for mediating MDR in SLK cells selected with either HIV-PIs alone or in combination with doxorubicin. Therefore, the roles that ABCB1 and drug cocktails play in mediating MDR in KS in vivo should be evaluated.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Resistencia a Múltiples Medicamentos/efectos de los fármacos , Resistencia a Antineoplásicos/efectos de los fármacos , Infecciones por VIH/tratamiento farmacológico , Inhibidores de la Proteasa del VIH/farmacología , Sarcoma de Kaposi/tratamiento farmacológico , Sarcoma de Kaposi/metabolismo , Subfamilia B de Transportador de Casetes de Unión a ATP , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/biosíntesis , Antibióticos Antineoplásicos/farmacología , Sulfato de Atazanavir , Western Blotting , Línea Celular Tumoral , Doxorrubicina/farmacología , Sinergismo Farmacológico , Citometría de Flujo , Técnica del Anticuerpo Fluorescente , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Infecciones por VIH/complicaciones , Humanos , Indinavir/farmacología , Lopinavir , Nelfinavir/farmacología , Oligopéptidos/farmacología , Piridinas/farmacología , Pirimidinonas/farmacología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Ritonavir/farmacología , Sarcoma de Kaposi/virología , Resultado del Tratamiento
2.
Clin Pharmacol Ther ; 86(4): 368-77, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19625998

RESUMEN

P-glycoprotein (P-gp), an efflux transporter, controls the pharmacokinetics of various compounds under physiological conditions. P-gp-mediated drug efflux has been suggested as playing a role in various disorders, including multidrug-resistant cancer and medication-refractory epilepsy. However, P-gp inhibition has had, to date, little or no clinically significant effect in multidrug-resistant cancer. To enhance our understanding of its in vivo function under pathophysiological conditions, substrates of P-gp have been radiolabeled and imaged using single-photon emission computed tomography (SPECT) and positron emission tomography (PET). To accurately quantify P-gp function, a radiolabeled P-gp substrate should be selective for P-gp, produce a large signal after P-gp blockade, and generate few radiometabolites that enter the target tissue. Furthermore, quantification of P-gp function via imaging requires pharmacological inhibition of P-gp, which requires knowledge of P-gp density at the target site. By meeting these criteria, imaging can elucidate the function of P-gp in various disorders and improve the efficacy of treatments.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Radiofármacos , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/metabolismo , Transporte Biológico/fisiología , Barrera Hematoencefálica/metabolismo , Resistencia a Múltiples Medicamentos , Epilepsia/tratamiento farmacológico , Epilepsia/metabolismo , Humanos , Modelos Biológicos , Neoplasias/tratamiento farmacológico , Neoplasias/metabolismo , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/metabolismo , Farmacocinética , Tomografía de Emisión de Positrones , Radiofármacos/farmacocinética , Tomografía Computarizada de Emisión de Fotón Único
3.
Ann N Y Acad Sci ; 1099: 204-14, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17446460

RESUMEN

Cyclosporin A (CsA) is an immunosuppressive drug commonly given to transplant patients. Its application is accompanied by severe side effects related to calcium, among them hypertension and nephrotoxicity. The Na+/Ca2+ exchanger (NCX) is a major calcium regulator expressed in the surface membrane of all excitable and many nonexcitable tissues. Three genes, NCX1, NCX2, and NCX3 code for Na+/Ca2+ exchange activity. NCX1 gene products are the most abundant. We have shown previously that exposure of NCX1-transfected HEK 293 cells to CsA, leads to concentration-dependent reduction of Na+/Ca2+ exchange activity and surface expression, without a reduction in total cell-expressed NCX1 protein. We show now that the effect of CsA on NCX1 protein expression is not restricted to transfected cells overexpressing the NCX1 protein but exhibited also in cells expressing endogenously the NCX1 protein (L6, H9c2, and primary smooth muscle cells). Exposure of NCX2- and NCX3-transfected cells to CsA results also in reduction of Na+/Ca2+ exchange activity and surface expression, though the sensitivity to the drug was lower than in NCX1-transfected cells. Studying the molecular mechanism of CsA-NCX interaction suggests that cyclophilin (Cyp) is involved in NCX1 protein expression and its modulation by CsA. Deletion of 426 amino acids from the large cytoplasmic loop of the protein retains the CsA-dependent downregulation of the truncated NCX1 suggesting that CsA-Cyp-NCX interaction involves the remaining protein domains.


Asunto(s)
Ciclosporina/farmacología , Regulación hacia Abajo/efectos de los fármacos , Intercambiador de Sodio-Calcio/metabolismo , Animales , Secuencia de Bases , Línea Celular , Células Cultivadas , Cartilla de ADN , Humanos , Pliegue de Proteína , Ratas , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
4.
Cancer Gene Ther ; 13(7): 648-57, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16498428

RESUMEN

SV40 vectors packaged in vitro (pseudovirions) are an efficient delivery system for plasmids up to 17.7 kb, with or without SV40 sequences. A truncated Pseudomonas exotoxin gene (PE38) was delivered into various human cells (HeLa, KB-3-1, human lymphoblastoids, and erythroleukemia cells), in vitro using pseudovirions. The number of viable cells was reduced significantly in the PE38-transduced cells. Human KB adenocarcinomas growing in mice were treated with intratumoral injection of PE38 packaged in vitro, and tumor size decreased significantly. Intraperitoneal treatments were as effective in reducing tumor size as intratumoral treatments. To check the viability of mock- or PE38-treated mice, every 4 days they were weighed, their blood was tested, and various tissues were screened for pathology. All parameters showed that the in vitro-packaged vectors, injected into tumors or intraperitoneally, caused no abnormalities in mice. The combined treatment of doxorubicin with in vitro-packaged PE38 reduced tumor size slightly more than each of the treatments separately. However, the combined treatment did not cause the weight loss seen with doxorubicin alone. These results indicate that SV40 in vitro packaging is an effective system for cancer gene delivery using two different routes of injection and in combination with chemotherapy.


Asunto(s)
ADP Ribosa Transferasas , Adenocarcinoma/terapia , Toxinas Bacterianas , Exotoxinas , Terapia Genética , Vectores Genéticos , Virus 40 de los Simios , Virión , Factores de Virulencia , ADP Ribosa Transferasas/genética , Adenocarcinoma/genética , Animales , Antibióticos Antineoplásicos/administración & dosificación , Toxinas Bacterianas/genética , Terapia Combinada , Doxorrubicina/administración & dosificación , Exotoxinas/genética , Femenino , Células HeLa , Humanos , Ratones , Ratones Desnudos , Neoplasias Experimentales/genética , Neoplasias Experimentales/terapia , Factores de Virulencia/genética , Ensamble de Virus , Exotoxina A de Pseudomonas aeruginosa
5.
Br J Cancer ; 91(2): 270-6, 2004 Jul 19.
Artículo en Inglés | MEDLINE | ID: mdl-15199393

RESUMEN

Reduced accumulation of cisplatin is the most consistent feature seen in cisplatin-resistant (CP-r) cells that are cross-resistant to other cytotoxic compounds, such as methotrexate. In this report, defective uptake of a broad range of compounds, including [(14)C]-carboplatin, [(3)H]MTX, [(3)H]folic acid (FA), [(125)I]epidermal growth factor, (59)Fe, [(3)H]glucose, and [(3)H]proline, as well as (73)As(5+) and (73)As(3+), was detected in CP-r human hepatoma and epidermal carcinoma cells that we have previously shown are defective in fluid-phase endocytosis. Downregulation of several small GTPases, such as rab5, rac1, and rhoA, which regulate endocytosis, was found in CP-r cells. However, expression of an early endosomal protein and clathrin heavy chain was not changed, suggesting that the defective endocytic pathway is clathrin independent. Reduced expression of the cell surface protein, folate-binding protein (FBP), which is a carrier for the uptake of MTX, was also observed in the CP-r cells by confocal immunofluorescence microscopy and Real-Time PCR. Reactivation of the silenced FBP gene in the CP-r cells by a DNA demethylation agent, 2-deoxy-5-aza-cytidine (DAC) demonstrates that hypermethylation occurred in the CP-r cells. The uptake of [(14)C]carboplatin, [(3)H]FA, and [(3)H]MTX increased in an early stage CP-r cell line (KB-CP1) after treatment with DAC. Both a defective endocytic pathway and DNA hypermethylation resulting in the downregulation of small regulatory GTPases and cell surface receptors contribute to the reduced accumulation of a broad range of compounds in CP-r cells.


Asunto(s)
Antineoplásicos/farmacología , Azacitidina/análogos & derivados , Proteínas Portadoras/genética , Cisplatino/farmacología , Metilación de ADN , Resistencia a Antineoplásicos/genética , Regulación Neoplásica de la Expresión Génica/fisiología , Proteínas de Unión al GTP Monoméricas/genética , Receptores de Superficie Celular/genética , Azacitidina/farmacología , Carboplatino/farmacología , Proteínas Portadoras/metabolismo , Supervivencia Celular/efectos de los fármacos , Decitabina , Regulación hacia Abajo , Endocitosis/fisiología , Receptores de Folato Anclados a GPI , Ácido Fólico/farmacología , Humanos , Immunoblotting , Metotrexato/farmacología , Proteínas de Unión al GTP Monoméricas/metabolismo , ARN Mensajero/metabolismo , Receptores de Superficie Celular/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células Tumorales Cultivadas/efectos de los fármacos
6.
Br J Cancer ; 88(8): 1327-34, 2003 Apr 22.
Artículo en Inglés | MEDLINE | ID: mdl-12698203

RESUMEN

We isolated human KB adenocarcinoma cisplatin-resistant (CP-r) cell lines with multidrug-resistance phenotypes because of reduced accumulation of cisplatin and other cytotoxic compounds such as methotrexate and heavy metals. The uptake of horseradish peroxidase (HRPO) and Texas Red dextran was decreased several-fold in KB-CP-r cells, indicating a general defect in fluid-phase endocytosis. In contrast, although EGF receptors were decreased in amount, the kinetics of EGF uptake, a marker of receptor-mediated endocytosis, was similar in sensitive and resistant cells. However, 40-60% of the (125)I-EGF released into the medium after uptake into lysosomes of KB-CP-r cells was TCA precipitable as compared to only 10% released by sensitive cells. These results indicate inefficient degradation of internalised (125)I-EGF in the lysosomes of KB-CP-r cells, consistent with slower processing of cathepsin L, a lysosomal cysteine protease. Treatment of KB cells by bafilomycin A(1), a known inhibitor of the vacuolar proton pump, mimicked the phenotype seen in KB-CP-r cells with reduced uptake of HRPO, (125)I-EGF, (14)C-carboplatin, and release of TCA precipitable (125)I-EGF. KB-CP-r cells also had less acidic lysosomes. KB-CP-r cells were crossresistant to Pseudomonas exotoxin, and Pseudomonas exotoxin-resistant KB cells were crossresistant to cisplatin. Since cells with endosomal acidification defects are known to be resistant to Pseudomonas exotoxin and blocking of endosomal acidification mimics the CP-r phenotype, we conclude that defective endosomal acidification may contribute to acquired cisplatin resistance.


Asunto(s)
Línea Celular Tumoral/fisiología , Cisplatino/toxicidad , Endocitosis/fisiología , Lisosomas/fisiología , Transporte Biológico , Carboplatino/farmacocinética , Carcinoma de Células Escamosas , Línea Celular Tumoral/ultraestructura , Resistencia a Antineoplásicos , Endocitosis/efectos de los fármacos , Factor de Crecimiento Epidérmico/metabolismo , Peroxidasa de Rábano Silvestre/farmacocinética , Humanos , Lisosomas/efectos de los fármacos
7.
Proc Natl Acad Sci U S A ; 99(20): 13096-101, 2002 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-12235361

RESUMEN

For skin gene therapy, achieving prolonged high-level gene expression in a significant percentage of keratinocytes (KC) is difficult because we cannot selectively target KC stem cells. We now demonstrate that topical colchicine treatment can be used to select, in vivo, KC progenitor cells transduced with the multidrug resistance gene (MDR1). When human skin equivalents containing MDR1-transduced KC were grafted onto immunocompromised mice, topical colchicine treatments significantly increased (7-fold) the percentage of KC expressing MDR1, compared to vehicle-treated controls, for up to 24 wk. Topical colchicine treatment also significantly enhanced the amount of MDR1 protein expressed in individual KC. Furthermore, quantitative real-time PCR analysis of MDR1 transgene copy number demonstrates that topical colchicine treatment selects and enriches for KC progenitor cells in the skin that contain and express MDR1. For clinical skin gene therapy applications, this in vivo selection approach promises to enhance both the duration and expression level of a desired therapeutic gene in KC, by linking its expression to the MDR1 selectable marker gene.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Colchicina/farmacología , Terapia Genética/métodos , Queratinocitos/metabolismo , Transgenes , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Animales , Células Cultivadas , Relación Dosis-Respuesta a Droga , Fibroblastos/metabolismo , Citometría de Flujo , Humanos , Ratones , Mitosis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factores de Tiempo
8.
Hum Gene Ther ; 12(8): 945-53, 2001 May 20.
Artículo en Inglés | MEDLINE | ID: mdl-11387059

RESUMEN

Potential applications of the MDR1 multidrug transporter in gene therapy include protecting sensitive bone marrow cells against cytotoxic drugs during cancer chemotherapy and serving as a dominant selectable marker when coexpressed with a corrective passenger gene. To address safety concerns associated with integrating viral systems, such as retroviruses, we tested the feasibility of maintaining a nonvirally delivered MDR1 gene (pEpiHaMA) episomally. An MDR1 vector containing the Epstein-Barr virus (EBV) origin of replication (OriP) and its nuclear retention protein (EBNA-1) was transfected into human (KB-3-1) cells. MDR1 was expressed at a higher level in cells carrying the episomal vector, pEpiHaMA, compared with the vector lacking sequences needed for episomal maintenance (pHaMA). Furthermore, more drug-resistant KB-3-1 colonies were obtained on selection after transfection with pEpiHaMA. These observations correlated with longer maintenance of episomes in cells transfected with pEpiHaMA. In addition, episomes could still be recovered for more than 1 month from tumor explants in nude mice that were injected with pEpiHaMA-liposome complexes after drug selection, suggesting that these constructs can be maintained extrachromosomally in vivo.


Asunto(s)
Genes MDR/genética , Terapia Genética/métodos , Plásmidos/genética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/biosíntesis , Animales , Antígenos CD34/biosíntesis , Núcleo Celular/metabolismo , Separación Celular , Antígenos Nucleares del Virus de Epstein-Barr/genética , Citometría de Flujo , Técnicas de Transferencia de Gen , Vectores Genéticos , Células HeLa , Herpesvirus Humano 4/genética , Humanos , Liposomas/metabolismo , Ratones , Modelos Genéticos , Origen de Réplica , Factores de Tiempo , Transfección , Transgenes , Células Tumorales Cultivadas
9.
J Soc Pediatr Nurs ; 6(2): 55-64, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11326462

RESUMEN

ISSUES AND PURPOSE: To examine the roles of public policy and poverty on the rising number of children in family foster care, and to examine the impact of different types of family foster care on children's well-being. CONCLUSIONS: Recent changes in welfare legislation increase the likelihood of family poverty, with a subsequent increase in the number of children in out-of-home care. Greater emphasis needs to be placed on preventing entry into out-of-home care, improving the quality of foster care, and giving children a voice in care decisions. PRACTICE IMPLICATIONS: Nurses have important roles to play in the prevention of family dissolution, the design of healthcare delivery systems for children in foster care, in evaluating and educating all types of foster families, and as advocates in legal and legislative proceedings.


Asunto(s)
Protección a la Infancia/legislación & jurisprudencia , Cuidados en el Hogar de Adopción/organización & administración , Política Pública , Calidad de la Atención de Salud , Niño , Cuidados en el Hogar de Adopción/métodos , Cuidados en el Hogar de Adopción/estadística & datos numéricos , Humanos , Concesión de Licencias , Enfermería , Pobreza , Prevención Primaria , Factores de Riesgo , Estados Unidos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA